## Author Index, Volume 6

**A**  
Acquiodro C, 522  
Akazawa M, 107  
Akehurst RL, 3  
Anderhub H, 75  
Andrews EB, 85  
Antoñanzas F, 126, S52  
Arguedas MR, 457  
Avey SG, 505

**B**  
Balda E, 574  
Banz K, 551  
Barbieri M, 407  
Battleman DS, 137  
Berger ML, 175  
Berzon R, 522, 560  
Blackhouse G, 116  
Botteman MF, 59  
Brandt S, 59  
Brooks J, 90  
Brown R, 407  
Buesching DP, 40  
Burge RT, 574

**C**  
Cabanela RL, 144  
Callahan M, 137  
Caprini JA, 59  
Carter D, 438  
Christenson DB, 18  
Christos P, 137  
Clark MA, 90  
Cohen AT, 59  
Cramer J, 566  
Cram P, 466  
Crawley JA, 560  
Crown WH, 90, 448

**D**  
Dasbach EJ, 88  
Davey P, 90  
De Hollander AEM, 494  
DeVincenzo J, 100  
Doucette WR, 51  
Dowie J, 403  
Drummond M, 407, 438, S74  
Dubois D, 522

**E**  
Eaton S, 85  
Efimba M, 137  
Eloubeidi MA, 457  
Enns RA, 457  
Ernst ME, 51

**F**  
Etemad LR, 425  
Ewing MM, 59  
Fendrick M, 407, 466  
Fifer SK, 40  
Franic DM, 483  
Fry RN, 505  
Fu AZ, 18  
Fullerton P, 407

**G**  
Gabriel SE, 144  
Gagnon YM, 457  
Garrison L, S1  
Garrison LP Jr., 6  
Goeree R, 116  
Goertz A, 551  
Graham JD, 417  
Greiner W, S20  
Guo JD, 18

**H**  
Hammerschmidt T, 551  
Hay JW, 425  
Henke CJ, 40  
Herold M, 167  
Hettiarachchi J, 438  
Hieke K, 167  
Hillson E, 560  
Holdsworth MT, 158  
Hoogenveen RT, 494  
Hornberger J, 9  
Hutchins D, 90  
Hutter JJ, 158

**I**  
Iyer SS, 51

**J**  
Jackson J, 9  
Jacobson P, 100  
Jansen J, 494  
Jimison HB, 29  
Johannesson M, 9  
Jönsson B, S74

**K**  
Kamath CC, 144  
Khandker RK, 534  
King AB, 574  
Kirk G, 566  
Koopmanschap MA, S46  
Kosa J, 126  
Kremers HM, 144  
Krol W, 566  
Krystal J, 566  
Kulasingam SL, 542

**L**  
Leader S, 100  
Leidy NK, 522  
Lenderking WR, 501, 560  
Le Pen C, S10  
Levy AR, 457  
Litt M, 564  
Liu GG, 18  
Loeb M, 116  
Lowy A, 75  
Luce BR, 9  
Lucioni C, S31

**M**  
Mapelli V, S31  
Marcin JR, 100  
Marks AS, 98  
Mark TL, 474  
Marquis P, 522  
Martin BC, 90  
Matchar DB, 542  
Mather D, 404  
Mathias SD, 40  
Mauskopf J, 1  
McCabe C, 9  
McCrorry DC, 542  
McGuire A, S64  
Moore D, 560  
Motheral B, 90  
Mulder I, 494  
Murray DL, 100

**N**  
Nadipelli V, 59, 126  
Nathan R, 448  
Neiss A, 531  
Neumann P, 407  
Nuijten MJC, 126

**O**  
O’Brien B, 9  
O’Brien BJ, 116, 501  
O’Fallon WM, 144  
Olufade A, 448

**P**  
Paltiel AD, 107  
Pang F, 438  
Parpia T, 438  
Pashos CL, 59, 560
<table>
<thead>
<tr>
<th>Author Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patel KK, 595</td>
</tr>
<tr>
<td>Pathak DS, 483</td>
</tr>
<tr>
<td>Patrick DL, 40, 595</td>
</tr>
<tr>
<td>Patwardhan MB, 542</td>
</tr>
<tr>
<td>Potter LP, 40</td>
</tr>
<tr>
<td>R</td>
</tr>
<tr>
<td>Raisch DW, 158</td>
</tr>
<tr>
<td>Revicki D, 522</td>
</tr>
<tr>
<td>Rioux KP, 457</td>
</tr>
<tr>
<td>Rosenheck R, 566</td>
</tr>
<tr>
<td>Roth D, 534</td>
</tr>
<tr>
<td>Rothman M, 522</td>
</tr>
<tr>
<td>Rubio-Terrés C, 126</td>
</tr>
<tr>
<td>Rutschmann OT, 542</td>
</tr>
<tr>
<td>Rutten FFH, S46</td>
</tr>
<tr>
<td>S</td>
</tr>
<tr>
<td>Samsa GP, 542</td>
</tr>
<tr>
<td>Santos MT, 584</td>
</tr>
<tr>
<td>Schmechel DE, 542</td>
</tr>
<tr>
<td>Schonfeld WH, 40</td>
</tr>
<tr>
<td>Schulenburg, JMG, S20</td>
</tr>
<tr>
<td>Schwenkglenks M, 75</td>
</tr>
<tr>
<td>Schwermann T, S20</td>
</tr>
<tr>
<td>Sindelar JL, 107</td>
</tr>
<tr>
<td>Smieja M, 116</td>
</tr>
<tr>
<td>Smit HA, 494</td>
</tr>
<tr>
<td>Smith DG, 436</td>
</tr>
<tr>
<td>Smith MW, 448</td>
</tr>
<tr>
<td>Stang P, 90</td>
</tr>
<tr>
<td>Stephens JM, 59</td>
</tr>
<tr>
<td>Suarez C, 126</td>
</tr>
<tr>
<td>Subramanian S, 534</td>
</tr>
<tr>
<td>Sullivan SD, 505</td>
</tr>
<tr>
<td>Swait J, 474</td>
</tr>
<tr>
<td>Szucs TD, 75</td>
</tr>
<tr>
<td>T</td>
</tr>
<tr>
<td>Taylor R, 407</td>
</tr>
<tr>
<td>Towse A, S1</td>
</tr>
<tr>
<td>U</td>
</tr>
<tr>
<td>Ungar WJ, 584</td>
</tr>
<tr>
<td>V</td>
</tr>
<tr>
<td>Van Genugten MLL, 494</td>
</tr>
<tr>
<td>Vanness DJ, 144</td>
</tr>
<tr>
<td>Veenstra DL, 595</td>
</tr>
<tr>
<td>Vijan S, 466</td>
</tr>
<tr>
<td>W</td>
</tr>
<tr>
<td>Wagenpfeil S, 551</td>
</tr>
<tr>
<td>Wagner TH, 29</td>
</tr>
<tr>
<td>Weinstein MC, 9</td>
</tr>
<tr>
<td>Wells N, 438</td>
</tr>
<tr>
<td>Whitelaw G, 137</td>
</tr>
<tr>
<td>Winter SS, 158</td>
</tr>
<tr>
<td>Wolbrink A, 466</td>
</tr>
<tr>
<td>Wong PK, 532</td>
</tr>
<tr>
<td>Woodcock J, 420</td>
</tr>
<tr>
<td>Worley D, 574</td>
</tr>
<tr>
<td>Wutzler P, 551</td>
</tr>
<tr>
<td>Y</td>
</tr>
<tr>
<td>Yang H, 100</td>
</tr>
<tr>
<td>Z</td>
</tr>
<tr>
<td>Zarin DA, 542</td>
</tr>
</tbody>
</table>
Subject Index, Volume 6

A
Absenceism costs, influenza-related, 107
Abstracts
  ISPOR Eight Annual International Meeting, 177–399
  ISPOR Sixth Annual European Congress, 605–809
Academy of Managed Care Pharmacy, Format for Formulary Submissions, 501, 505
ACE inhibitor usage, impact of insurance on, 18
Acetaminophen, cost-effectiveness for knee osteoarthritis, 144
Alcoholism medications
  compliance feedback and monitoring, 566
  forecasting physician's preferred rate of prescribing, 474
Allergic rhinitis, seasonal vs. perennial, 448
Alzheimer's disease, functional neuroimaging, 542
AMCP, Format for Formulary Submissions, 501, 505
Angiotensin-converting enzyme inhibitor usage, impact of insurance on, 18
Antihypertensive drug usage, impact of insurance on, 18
Anxiety treatment, primary care utilization after, 40
AQLQ, application in clinical trials, 595
Arthritis drug-related problems, HRQoL and, 51
Asthma cost, in Swiss adult cohort, 75
Asthma Quality of Life Questionnaire, application in clinical trials, 595
Automated external defibrillators, cost-effectiveness on commercial aircraft, 466

B
Beta-blocker usage, impact of insurance on, 18
Calcium channel blocker usage, impact of insurance on, 18
Cardiac arrest, automated external defibrillators on commercial aircraft and, 466
Cardiopulmonary bypass surgery renal dysfunction, economic consequences of, 137
Care settings, for chemotherapy-induced febrile neutropenia, 158
Celecoxib, cost-effectiveness for knee osteoarthritis, 144
Chemotherapy drug delivery costs, international assessment of, 167
Chemotherapy-induced febrile neutropenia, care settings for, 158

Children
care settings for chemotherapy-induced febrile neutropenia, 158
health economics literature, evaluation of, 584
infants, cost of RSV hospitalization, 100
CHOP drug delivery costs, international assessment of, 167
Claims data analysis
  checklist for databases, 85
  databases in pharmacoeconomic studies, 88
  in drug development, 522
  PTCA vs. stenting, 532, 534
Clinical trials
  application of patient-generated outcome measures in, 595
  medication compliance and feedback in, 566
Compliance, continuous monitoring and feedback, 566
Computerized health information, consumer medical care demand and, 29
Confidentiality, Format for Formulary Submissions and, 505
Conjoint analysis, in forecasting drug prescription patterns, 474
Consumer demand for medical care, computerized health information and, 29
COP drug delivery costs, international assessment of, 167
Cost analysis
  asthma in Swiss adult cohort, 75
  chemotherapy drug delivery, 167
  influenza-related work absenteeism, 107
  IV proton pump inhibitors for acute peptic ulcer bleeding, 457
  long-term complications of DVT after total hip replacement, 59
  osteoporosis in Florida, 574
  PTCA vs. stenting, 532, 534
  renal dysfunction after cardiopulmonary bypass surgery, 137
  RSV infant hospitalization, 100
  smoking-related disease, 494
Cost-effectiveness analysis
  alternative treatments for knee osteoarthritis, 144
  enoxaparin in Spain, 126
  for drug reimbursement submissions, 501
  for managed care formulary submissions, 505
  impact of passive benefits on, 466
  in health policy, 417
  in health-care decision making, 407
  Medicare drug benefit program, 425
migraine treatment, 436, 438
oseltamivir for influenza, 116

D
Data, for mathematical models, 9
Decision analytic modeling
ISPOR good practice principles for, 6
reliable, need for, 3
Decision makers
health economic data for, 404
needs of, 403
Decision making, pharmacoeconomic/health
economic information in, 407
Deep vein thrombosis, after total hip replacement,
   cost of, 59
Depression treatment, primary care utilization after,
   40
Disease severity, asthma costs in Swiss adult cohort
   and, 75
Diuretic usage, impact of insurance on, 18
Donepezil, for Alzheimer's disease, 542
Drug costs, managed care formulary submissions
   and, 505
Drug delivery costs for chemotherapy, international
   assessment of, 167
Drug use patterns, seasonal vs. perennial allergic
   rhinitis, 448
Drug utilization, in Medicare drug benefit program,
   425
Drug-related problems in musculoskeletal disorders,
   HRQoL and, 51
Dynamic modeling, future burden of smoking-related
disease in Netherlands, 494

E
Economic burden
   of asthma, in Swiss adult cohort, 75
   of osteoporosis in Florida, 574
   of post-thrombotic syndrome, 59
   of smoking-related disease in Netherlands in
   future, 494
Economic evaluation. See also Cost analysis; Cost-
effectiveness analysis
   of migraine treatment, 436,
   438
   of renal dysfunction after cardiopulmonary bypass
   surgery, 137
Pediatric Quality Appraisal Questionnaire and,
   584
validation of EVITA, 551
Economic information, in health-care decision
   making, 407
Economic Varicella Vaccination Tool, validation of,
   551
Eletriptan cost-effectiveness, for migraines, 436, 438
Enoxaparin, cost-effectiveness in Spain, 126
Evidence-based medicine, managed care formulary
   submissions and, 505
EVITA, validation of, 551
Extraesophageal reflux, HRQL and, 560

F
FDA, managed care formulary submissions and, 505
Febrile neutropenia, chemotherapy-induced, 158
Fludarabine delivery costs, international assessment
   of, 167
Food and Drug Administration, managed care
   formulary submissions and, 505
Forecasting, physician's preferred rate of prescribing
   alcohol medications, 474
Formulary submissions, AMCP format for, 505
Fracture incidence, in estimating burden of
   osteoporosis in Florida, 574
Functional neuroimaging, for Alzheimer's dementia,
   542
Gastroesophageal reflux, HRQL and, 560
Gastrointestinal bleeding, cost analysis of IV proton
   pump inhibitors for, 457
GERD, HRQL and, 560
Gerontology, cost-effectiveness of Medicare drug
   benefit program, 425
Graphic positioning scale, vs. traditional scaling
   measures, 483

H
Health economic data, for decision makers, 404
Health economic models, validation of, 551
Health economics literature evaluation, pediatric,
   584
Health information, consumer demand for medical
   care and, 29
Health policy
cost-effectiveness analysis in, 417
in Florida, estimating burden of osteoporosis and, 574
Health-care decision making,
   pharmacoeconomic/health economic
   information in, 407
Health-related quality of life (HRQoL)
application in clinical trials, 595
evaluating, patient-reported outcomes and, 522
in musculoskeletal disorders, drug-related
   problems and, 51
laryngopharyngeal reflux disease and, 560
primary care utilization after mental health care
   and, 40
Hip fracture incidence, in estimating burden of
   osteoporosis in Florida, 574
Home care, vs. hospital-based
care for febrile neutropenia, 158
Hospital, *vs.* home care for febrile neutropenia, 158
Hypertension treatment, impact of insurance on, 18

I
Individualized measures, application in clinical trials, 595
Infants, cost of RSV hospitalization, 100
Influenza
  absenteeism costs and, 107
  oseltamivir cost-effectiveness for, 116
Insurance, antihypertensive drug usage and, 18
Interactive health communication, consumer demand for medical care and, 29
Internet, consumer demand for medical care and, 29
ISPOR Task Force on Good Research Practices
  good practice modeling principles, 6
  modeling studies, 9

J
Joint National Committee hypertension treatment guidelines, insurance and, 18

K
Kidney dysfunction after cardiopulmonary bypass surgery, economic consequences of, 137
Knee osteoarthritis alternative treatments, cost-effectiveness of, 144

L
Laryngopharyngeal reflux disease, HRQL and, 560
Longitudinal database research, additional considerations for, 85
Low back pain drug-related problems, HRQL and, 51

M
Manufacturers, managed care formulary submissions and, 505
Markov modeling
  for Alzheimer’s disease diagnosis, 542
  in estimating burden of osteoporosis in Florida, 574
  of enoxaparin cost-effectiveness in Spain, 126
MEDENOX trial, enoxaparin cost-effectiveness in Spain, 126
Medical Expenditure Panel Survey, costs of influenza-related absenteeism, 107
Medical resource use patterns, seasonal *vs.* perennial allergic rhinitis, 448
Medical utilization, computerized health information and, 29
Medicare
  drug benefit program, cost-effectiveness analysis, 425
  PTCA *vs.* stenting, 532, 534
Medication compliance, monitoring in clinical trials, 566
MEPS, costs of influenza-related absenteeism, 107
Migraine treatment, cost-effectiveness of, 436, 438
Misoprostol, cost-effectiveness for knee osteoarthritis, 144
Monte Carlo simulations, costs of IV proton pump inhibitors for GI bleeding, 457
Musculoskeletal disorder drug-related problems, HRQL and, 51

N
Naltrexone, compliance feedback and monitoring, 566
National Institute for Clinical Excellence, decision analytic modeling and, 3
Netherlands, future burden and costs of smoking-related disease, 494
Neutropenia, febrile chemotherapy-induced, 158
NICE, decision analytic modeling and, 3
Non-Hodgkin’s lymphoma drug delivery costs, international assessment of, 167
Nonsteroidal antiinflammatory drugs, cost-effectiveness for knee osteoarthritis, 144

O
Oseltamivir, cost-effectiveness for influenza, 116
Osteoporosis, estimating current and future costs in Florida, 574
Outcomes research. See also Patient-reported outcomes
  additional considerations for, 85
  effect of mental health care on primary care utilization, 40
  of renal dysfunction after cardiopulmonary bypass surgery, 137
  risk management issues, 420
Outpatient care, for chemotherapy-induced febrile neutropenia, 158

P
Passive benefits, of automated external defibrillators on commercial aircraft, 466
Patient Reported Outcomes Harmonization Group, task force report of, 503
Patient-Generated Index, application in clinical trials, 595
Patient-reported outcomes
  in clinical trials, 595
  in drug review and evaluation process, 522
  task force report on, 503
Pediatric Quality Appraisal Questionnaire, for evaluating pediatric health economics literature, 584
Peptic ulcers, cost analysis of IV proton pump inhibitors for, 457
Subject Index

Percutaneous transluminal coronary angioplasty, vs.
stenting, 532, 534
Perennial allergic rhinitis, drug and medical resource
use patterns, 448
PET, for Alzheimer’s disease, 542
PGI, application in clinical trials, 595
Pharmaceutical care in Medicare drug benefit
program, cost-effectiveness analysis, 425
Pharmaco economics information, in health-care
decision making, 407
Positron emission tomography, for Alzheimer’s
disease, 542
Post-thrombotic syndrome, cost of, 59
PQAQ, for evaluating pediatric health economics
literature, 584
Premature infants, cost of RSV hospitalization, 100
Prescribing patterns, forecasting for alcoholism
medications, 474
Probabilistic sensitivity analysis, cost of IV proton
pump inhibitors for GI bleeding, 457
Productivity costs, influenza-related absenteeism and,
107
Proton pump inhibitors, cost analysis for GI
bleeding, 457
PTCA, vs. stenting, 532, 534
Public access defibrillation, impact of passive benefits
on cost-effectiveness analysis, 466
Public health, future burden of smoking-related
disease in Netherlands, 494

Q
Quality, of health-care decision models, 9

R
Race, burden of osteoporosis in Florida and, 574
Reflux laryngitis, HRQL and, 560
Regulatory issues, drug review and evaluation
process and, 522
Reliability, of longitudinal database research, 85
Renal dysfunction after cardiopulmonary bypass
surgery, economic consequences of, 137
Repertory Grid, application in clinical trials, 595
Research design, for retrospective database studies,
85
Resource use, asthma cost in Swiss adult cohort and,
75
Respiratory syncytial virus, infant hospitalization
costs, 100
Retrospective claims data analysis, PTCA vs.
stenting, 532, 534
Retrospective databases, checklist for, 85
Risk management issues, for outcomes research, 420
Rofecoxib, cost-effectiveness for knee osteoarthritis,
144
RSV, infant hospitalization costs, 100

S
Scenario analysis, future burden of smoking-related
disease in Netherlands, 494
Schedule for the Evaluation of Individual Quality of
Life, application in clinical trials, 595
Seasonal allergic rhinitis, drug and medical resource
use patterns, 448
SEIQoL, application in clinical trials, 595
Selective COX-2 inhibitors, cost-effectiveness for
knee osteoarthritis, 144
Selective serotonin receptor agonists for migraines,
cost-effectiveness of, 436, 438
Self-care information, consumer demand for medical
care and, 29
Smoking-related disease, future burden in
Netherlands, 494
Somatization, primary care utilization after mental
health care and, 40
Spain, enoxaparin cost-effectiveness in, 126
Standard gamble, respondent acceptability of,
483
Stated preference modeling, for forecasting, 474
Statistics, for retrospective database studies, 85
Stenting, vs. percutaneous transluminal coronary
angioplasty, 532, 534
Sumatriptan for migraines, cost-effectiveness of, 436,
438
Switzerland, adult asthma patient costs in, 75

T
Total hip replacement surgery, post-thrombotic
syndrome costs and, 59
Traditional scaling measures, vs. graphic positioning
scale, 483

V
Validation
of health economic models, 551
of mathematical models, 9
of retrospective database studies, 85
Varicella vaccination, economic validation of, 551
Venous thromboembolism, costs after total hip
replacement, 59
Visual analog scale, respondent acceptability of, 483

W
Willingness to pay measures, respondent
acceptability of, 483